Serum test for assessment of patients with Bence Jones myeloma

Lancet. 2003 Feb 8;361(9356):489-91. doi: 10.1016/S0140-6736(03)12457-9.


Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain multiple myeloma. We aimed to compare a quantitative immunoassay for serum free-light-chains with urine tests. Of 224 patients with light-chain myeloma tested at entry to clinical trials, all were correctly identified from serum samples. During monitoring of 82 patients, changes in serum and urine free-light-chains corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained abnormal in serum in 73 patients. Serum assays could replace Bence Jones protein urine tests for patients with light-chain multiple myeloma.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bence Jones Protein / metabolism*
  • Clinical Trials as Topic
  • Follow-Up Studies
  • Humans
  • Immunoassay
  • Immunoglobulin Light Chains / blood
  • Multiple Myeloma / blood
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / drug therapy
  • Predictive Value of Tests
  • Reference Values


  • Immunoglobulin Light Chains
  • Bence Jones Protein